WhiteOak Capital Pharma and Healthcare Fund
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
Growthvine rating: 2/5 — ranked #59 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹16.70 (as of 2026-08-21) |
|---|
| AUM | ₹793 Cr |
|---|
| Expense ratio | 1.99% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ramesh Mantri |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -15.62% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 110.3% of NIFTY Pharma's upside and 83.4% of its downside.
Market cap allocation
| Large cap | 30.4% |
|---|
| Mid cap | 24.4% |
|---|
| Small cap | 45.3% |
|---|
Concentration
| Top 5 holdings | 29.9% |
|---|
| Top 10 holdings | 46.4% |
|---|
| Total holdings | 49 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 8.5%
- Torrent Pharmaceuticals Ltd. — 7.8%
- Laurus Labs Limited — 4.9%
- Apollo Hospitals Enterprises Ltd. — 4.8%
- Divis Laboratories Ltd. — 3.9%
- Max Healthcare Institute Limited — 3.8%
- Cipla Ltd. — 3.7%
- Sai Life Sciences Limited — 3.2%
- Zydus Lifesciences Limited — 2.9%
- Neuland Laboratories Limited. — 2.9%
Top sectors
- Pharma & Biotech — 59.8%
- Healthcare — 29.5%
- Chemicals — 3.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 21.6% | Q1 (Top) | #5 of 76 |
| 2025 | 0.1% | Q2 | #34 of 69 |